|Articles|September 22, 2022
COVID-19 Agent Molnupiravir
Author(s)YMC Europe GmbH
Molnupiravir, which is a prodrug, and its active agent β-d-N4-hydroxycytidine can be separated by using a YMC-Triart C18 UHPLC column and a MS-compatible mobile phase.
Newsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Related Content
Trending on LCGC International
1
Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling
2
Navigating Adverse Reactions in GLP-1 Treatment
3
Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets
4
Shifting GLP-1 Receptor Agonists from Proteins to Small Molecules
5
